Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Clinical Trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma
Graft Versus Host Disease

Interventions: Drug: carmustine
Drug: melphalan
Drug: etoposide
Drug: cytarabine
Drug: tacrolimus
Drug: methotrexate
Drug: sargramostim
Procedure: transplant

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-19

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 4

Registration Number: NCT00006747

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

and more 45 locations

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2017-11-29

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 213

Registration Number: NCT00005985

Locations: 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Adult Acute Lymphoblastic Leukemia in Remission

Interventions: Drug: imatinib mesylate
Drug: methotrexate
Drug: vincristine sulfate
Drug: leucovorin calcium
Procedure: peripheral blood stem cell transplantation
Procedure: autologous hematopoietic stem cell transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Radiation: total-body irradiation
Drug: tacrolimus
Biological: filgrastim
Drug: etoposide
Drug: cyclophosphamide
Drug: cytarabine
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2014-11-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00039377

Locations: 🇺🇸
Great Falls Clinic, Great Falls, Montana, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸
Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States

and more 94 locations

Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission

Phase 3

Completed

Conditions: Leukemia

Interventions: Biological: sargramostim
Drug: cyclophosphamide
Drug: asparaginase
Drug: cytarabine
Drug: dexamethasone
Drug: daunorubicin hydrochloride
Drug: etoposide
Drug: imatinib mesylate
Drug: leucovorin calcium
Drug: mercaptopurine
Drug: methotrexate
Drug: prednisone
Drug: thioguanine
Drug: vincristine sulfate
Procedure: allogeneic bone marrow transplantation
Radiation: radiation therapy
Procedure: autologous bone marrow transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-18

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 1929

Registration Number: NCT00002514

Locations: 🇺🇸
Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia, Pennsylvania, United States
🇺🇸
MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸
Swedish Medical Center, Englewood, Colorado, United States

and more 91 locations

Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: German Hodgkin's Lymphoma Study Group

Target Recruit Count: 220

Registration Number: NCT00025636

Locations: 🇧🇪
Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium
🇩🇪
Universitaetsklinikum Essen, Essen, Germany
🇩🇪
Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet, Greifswald, Germany

and more 41 locations

Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Myelodysplastic/Myeloproliferative Neoplasms
Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-19

Lead Sponsor: Medical Research Council

Registration Number: NCT00005863

Locations: 🇬🇧
Birmingham Heartlands Hospital, Birmingham, England, United Kingdom

Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: etoposide
Drug: ifosfamide
Drug: melphalan
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2016-01-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 118

Registration Number: NCT00003631

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Phase 1

Completed

Conditions: Recurrent Adult Hodgkin Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Childhood Non-Hodgkin Lymphoma
Refractory Childhood Hodgkin Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
T-Cell Chronic Lymphocytic Leukemia
T-Cell Prolymphocytic Leukemia
Recurrent Childhood Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cyclosporine
Drug: Cytarabine
Drug: Etoposide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: Therapeutic Autologous Lymphocytes
Radiation: Total-Body Irradiation

First Posted Date: 2003-01-27

Last Posted Date: 2020-01-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 76

Registration Number: NCT00005803

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸
LDS Hospital, Salt Lake City, Utah, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

and more 2 locations

Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Radiation: tositumomab and iodine I 131 tositumomab

First Posted Date: 2003-01-27

Last Posted Date: 2023-09-01

Lead Sponsor: University of Nebraska

Target Recruit Count: 50

Registration Number: NCT00006695

Locations: 🇺🇸
UNMC Eppley Cancer Center at University of Nebraska Medical Center, Omaha, Nebraska, United States

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: leucovorin calcium
Drug: methotrexate
Drug: prednisone
Drug: vincristine sulfate
Drug: Allopurinol

First Posted Date: 2003-01-27

Last Posted Date: 2023-08-21

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 105

Registration Number: NCT00039130

Locations: 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

and more 28 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy